RedHill Biopharma Announces Positive DSMB Futility Review for ...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
TEL AVIV, Israel and RALEIGH, N.C., Jan. 29, 2021, /PRNewswire-AsiaNet/ -- Following interim review of unblinded safety and efficacy data, independent DSMB unanimously recommends continuation of the global Phase 2/3 study of orally-administered opaganib for severe COVID-19 Opaganib targets a human cell component invo...
Authors: LATEST ASIANET NEWS RELEASES